Risks and benefits of citrate anticoagulation for continuous renal replacement therapy

Shum, HP; Wu, Yan; Chan, TM

doi:10.12809/hkmj144330

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Citrate is a well-known alternative anticoagulant for CRRT, and there was a significant reduction in the incidence of bleeding complications when citrate was used (risk ratio, 0.24; p = 0.02) (14). However, citrate may have side effects such as hypocalcemia and metabolic alkalosis (15). Additionally, most of the citrate anticoagulation methods require calcium administration to maintain systemic serum ionized calcium concentration in an appropriate range.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Due to osmotic effects, a reduced platelet and erythrocyte volume in citrate anti-coagulated blood samples is observed which is not the case with EDTA anticoagulated blood [19]. In addition to laboratory procedures, citrate anticoagulation is also used in renal replacement therapy [45].…”

Section: In Vitro Anticoagulationmentioning

confidence: 99%

Influence of different methods and anticoagulants on platelet parameter measurement

Mannuß

2020

Journal of Laboratory Medicine

View full text Add to dashboard Cite

Platelets are the smallest and perhaps the most versatile components of human blood. Besides their role in coagulation and the maintenance of vascular integrity, they are involved in many physiological processes, ranging from immune response and leukocyte recruitment to the production of antimicrobial peptides and immune-suppressive factors like TGF-β. These versatile abilities make platelets interesting for researchers from different disciplines. However, beside profound investigation into platelets’ physiological role, there is a need for correct, standardized and thus reproducible quantification of platelet parameters. Mean platelet volume (MPV) is a widespread prognostic marker for several conditions, such as, acute coronary syndrome, chronic kidney disease and liver cirrhosis. Platelet activation is regarded as a marker for inflammatory processes, for example in autoimmune diseases such as type-1 diabetes, systemic lupus erythematosus and rheumatoid arthritis. The monitoring of platelet function is relevant for patients receiving antiplatelet medication. Platelet parameter measurement is affected by the choice of in vitro anticoagulant, the measurement technology and the time delay after sampling. This review focuses on the pre-analytical variability that arises as a result of the use of different in vitro anticoagulants and analyzer technologies when determining platelet parameters, since, even approximately 180 years after the discovery of platelets, there is still no standardized procedure.

show abstract

“…Calcium replacement was provided by either calcium gluconate or calcium chloride solution infusion and was titrated to achieve a systemic ionized calcium (iCa) level of 1–1.2 mmol/L with postfilter iCa level of 0.25–0.3 mmol/L. [ 23 ] The overall fluid withdrawal rate was adjusted to achieve the desired fluid balance at the discretion of physician-in-charge. Each patient received at least one session of HCO treatment and further treatment sessions were conducted based on the clinician's decision.…”

Section: Aterials and M Ethodsmentioning

confidence: 99%

Treatment of acute kidney injury complicating septic shock with EMiC2 high-cutoff hemofilter: Case series

Shum

Chan

Yan

et al. 2017

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

Introduction:Extracorporeal blood purification therapies have been proposed to improve outcomes of patients with severe sepsis, with or without accompanying acute kidney injury (AKI), by removal of excessive inflammatory mediators.Materials and Methods:We report our experience with EMiC2 high-cutoff continuous venovenous hemofiltration/hemodialysis (HCO-CVVH/HD) in seven patients with AKI complicating septic shock.Results:The median treatment duration was 71 h, and the procedure was well tolerated. Trough serum albumin level of 20 g/L was observed after 2 h of treatment and none of the patients required albumin supplement. The hospital mortality rate was 29%, which appeared more favorable than the predicted mortality of 60%–78% based on disease severity scores. Circulating levels of interleukin-6 (IL-6), IL-10, and tumor necrosis factor-alpha improved over time.Conclusion:This case series shows that HCO-CVVH/CVVHD using EMiC2 hemofilter may provide good cytokine modulation, when used along with good quality standard sepsis therapy. A further large-scale prospective randomized controlled trial is recommended.

show abstract

Risks and benefits of citrate anticoagulation for continuous renal replacement therapy

Cited by 5 publications

References 30 publications

Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy

Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy

Influence of different methods and anticoagulants on platelet parameter measurement

Treatment of acute kidney injury complicating septic shock with EMiC2 high-cutoff hemofilter: Case series

Contact Info

Product

Resources

About